Bergen, Norway, 17 November 2021 - Reference is made to the stock exchange notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 9 November 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise of options pursuant to the Company's share option program. A total of 70,000 options were exercised and 70,000 new shares were issued at an average subscription price of NOK 15.00 per share.

 

The share capital increase has been duly registered in the Norwegian Register of Business Enterprises. Following such registration, the Company's share capital is NOK 8,845,525.50 divided into 88,455,255 shares, each with a nominal value of NOK 0.10.

 

-End-

 

Contacts

 

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

 

Rune Skeie

CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

 

Forward looking statements

 

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements

 

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

 

 

http://publish.ne.cision.com//Release/ViewReleaseHtml/C7E26D5060537EA8E0C856B0705FC7D6

https://mb.cision.com/Main/15728/3455837/1497862.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English